Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations

LC Tao, J Xu, T Wang, F Hua, JJ Li - Cardiovascular diabetology, 2022 - Springer
The triglyceride-glucose (TyG) index has been identified as a reliable alternative biomarker
of insulin resistance (IR). Recently, a considerable number of studies have provided robust …

Development of innovative biomaterials and devices for the treatment of cardiovascular diseases

Y Wang, G Li, L Yang, R Luo, G Guo - Advanced Materials, 2022 - Wiley Online Library
Cardiovascular diseases have become the leading cause of death worldwide. The
increasing burden of cardiovascular diseases has become a major public health problem …

2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on …

Writing Committee Members, JS Lawton… - Journal of the American …, 2022 - jacc.org
Aim The guideline for coronary artery revascularization replaces the 2011 coronary artery
bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines …

Coronary In-Stent Restenosis: JACC State-of-the-Art Review

G Giustino, A Colombo, A Camaj, K Yasumura… - Journal of the American …, 2022 - jacc.org
The introduction and subsequent iterations of drug-eluting stent technologies have
substantially improved the efficacy and safety of percutaneous coronary interventions …

Drug-coated balloons for coronary artery disease: third report of the international DCB consensus group

RV Jeger, S Eccleshall, WA Wan Ahmad, J Ge… - Cardiovascular …, 2020 - jacc.org
Although drug-eluting stents are still the default interventional treatment of coronary artery
disease, drug-coated balloons (DCBs) represent a novel alternative therapeutic strategy in …

Trends and outcomes of restenosis after coronary stent implantation in the United States

ID Moussa, D Mohananey, J Saucedo… - Journal of the American …, 2020 - jacc.org
Background There is a paucity of data on the burden of in-stent restenosis (ISR) in the
United States as well as on its presentation and appropriate treatment strategies. Objectives …

Restenosis of drug-eluting stents: a new classification system based on disease mechanism to guide treatment and state-of-the-art review

E Shlofmitz, M Iantorno, R Waksman - Circulation: Cardiovascular …, 2019 - Am Heart Assoc
Despite on-going evolution and iteration of drug-eluting stent (DES) technology, the
prevalence of in-stent restenosis (ISR) remains relatively unchanged, encompassing≈ 10 …

Exosome-eluting stents for vascular healing after ischaemic injury

S Hu, Z Li, D Shen, D Zhu, K Huang, T Su… - Nature biomedical …, 2021 - nature.com
Drug-eluting stents implanted after ischaemic injury reduce the proliferation of endothelial
cells and vascular smooth muscle cells and thus neointimal hyperplasia. However, the …

Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014

RA Byrne, M Joner, A Kastrati - European heart journal, 2015 - academic.oup.com
Modern-day stenting procedures leverage advances in pharmacotherapy and device
innovation. Patients treated with contemporary antiplatelet agents, peri-procedural …

[HTML][HTML] Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment

D Buccheri, D Piraino, G Andolina… - Journal of thoracic …, 2016 - ncbi.nlm.nih.gov
The lumen diameter reduction after percutaneous coronary intervention (PCI) is well known
as “restenosis”. This phenomenon is due to vessel remodeling/recoil in case of no-stent …